SiBone (NASDAQ:SIBN) CFO Sells $330,885.36 in Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 21,528 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $15.37, for a total value of $330,885.36. Following the sale, the chief financial officer directly owned 266,466 shares of the company’s stock, valued at approximately $4,095,582.42. This represents a 7.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, January 2nd, Anshul Maheshwari sold 5,229 shares of SiBone stock. The stock was sold at an average price of $19.64, for a total transaction of $102,697.56.
• On Thursday, December 18th, Anshul Maheshwari sold 18,542 shares of SiBone stock. The shares were sold at an average price of $20.15, for a total transaction of $373,621.30.
• On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The stock was sold at an average price of $20.00, for a total value of $2,000.00.
• On Friday, November 21st, Anshul Maheshwari sold 1,200 shares of SiBone stock. The stock was sold at an average price of $20.01, for a total value of $24,012.00.

SiBone Price Performance

SiBone stock traded up $0.49 during midday trading on Wednesday, reaching $15.74. The company’s stock had a trading volume of 569,275 shares, compared to its average volume of 551,190. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97. The stock’s 50 day simple moving average is $18.03 and its 200 day simple moving average is $16.86. SiBone has a fifty-two week low of $12.49 and a fifty-two week high of $21.89. The firm has a market capitalization of $682.97 million, a PE ratio of -30.86 and a beta of 0.69.

Analysts Set New Price Targets

Several research analysts have recently issued reports on SIBN shares. Canaccord Genuity Group lifted their price target on SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Morgan Stanley increased their price objective on SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Truist Financial boosted their target price on shares of SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. TD Cowen upgraded shares of SiBone to a “strong-buy” rating in a report on Tuesday, January 27th. Finally, Needham & Company LLC lifted their price target on shares of SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, SiBone presently has an average rating of “Moderate Buy” and a consensus target price of $24.33.

Hedge Funds Weigh In On SiBone

Hedge funds have recently made changes to their positions in the stock. First Light Asset Management LLC increased its holdings in shares of SiBone by 162.4% during the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock worth $99,249,000 after buying an additional 3,115,001 shares during the last quarter. Cadian Capital Management LP grew its position in SiBone by 96.8% during the fourth quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company’s stock valued at $23,094,000 after acquiring an additional 576,100 shares during the period. American Century Companies Inc. increased its stake in SiBone by 22.5% during the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock worth $41,777,000 after acquiring an additional 521,683 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of SiBone by 74.7% in the 3rd quarter. Wellington Management Group LLP now owns 853,266 shares of the company’s stock worth $12,560,000 after purchasing an additional 364,897 shares during the period. Finally, Peregrine Capital Management LLC acquired a new position in shares of SiBone in the 2nd quarter valued at about $6,664,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.